The Technical Analyst
AzurRx BioPharma Inc [AZRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
AzurRx BioPharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.07% $3.45
America/New_York / 22 sep 2021 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.43 mill |
| EPS: | -1.870 |
| P/E: | -1.845 |
| Earnings Date: | Aug 16, 2021 |
| SharesOutstanding: | 0.995 mill |
| Avg Daily Volume: | 0.713 mill |
| RATING 2022-02-09 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/20 | 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.845 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.31x |
| Company: PE -1.845 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.40 - 3.50 ( +/- 1.54%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-09-09 | Coelho Mary Theresa | Buy | 10 310 | Stock option (right to buy) |
| 2021-08-11 | Coelho Mary Theresa | Buy | 0 | |
| 2021-07-09 | Pennington James | Buy | 100 000 | Stock option (right to buy) |
| 2021-06-30 | Schneiderman Daniel H | Buy | 250 000 | Stock option (right to buy) |
| 2021-06-30 | Schneiderman Daniel H | Buy | 35 006 | Stock option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 81 transactions |
| Buy: 5 836 949 | Sell: 2 173 162 |
Forecast:
01:40 - $1.406
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.45 (2.07% ) |
| Volume | 0.629 mill |
| Avg. Vol. | 0.713 mill |
| % of Avg. Vol | 88.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AZRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AZRX
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
Latest Press Releases
2021-09-21 12:47:00 - Press Release
Azurrx Biopharma To Change Corporate Name To First Wave Biopharma Today
Company to begin trading on nasdaq under new ticker symbol, “fbwi”, effective september 22 company to begin trading on nasdaq under new ticker symbol, “fbwi”, effective september 22
2021-09-14 07:30:00 - Press Release
Azurrx Biopharma Ceo Issues Letter To Shareholders Regarding Recent Acquisition Of First Wave Bio And Creation Of First Wave Biopharma
Boca raton, fla., sept. 14, 2021 (globe newswire) -- azurrx biopharma, inc. (nasdaq:azrx), (“first wave biopharma” or the “company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (gi) diseases, today issued a letter to its shareholders from james sapirstein, president, chief executive officer and chairman, regarding its recently announced merger with first wave bio, inc. and adoption of the first wave biopharma name. the full text of the letter, which has also been posted to the company's website, is as follows:
2021-09-13 06:00:00 - Press Release
Azurrx Biopharma Announces Acquisition Of First Wave Bio And Its Proprietary Niclosamide Formulations Targeting Multi-billion Dollar Inflammatory Bowel Disease Indications
Azurrx biopharma to be renamed “first wave biopharma” and trade under new nasdaq ticker symbol, “fwbi”
2021-09-10 12:45:00 - Press Release
Azurrx Biopharma Announces Reverse Stock Split
Common stock will begin trading on split-adjusted basis on september 13, 2021 common stock will begin trading on split-adjusted basis on september 13, 2021
2021-09-10 08:30:00 - Press Release
Azurrx Biopharma Activates New Clinical Trial Sites In India For Phase 2 Reservoir Trial Evaluating Niclosamide For The Treatment Of Covid-19 Gastrointestinal Infections
Phase 2 placebo-controlled clinical trial to confirm safety of fw-1022 and investigate its ability to remove sars-cov-2 virus from the gi tract phase 2 placebo-controlled clinical trial to confirm safety of fw-1022 and investigate its ability to remove sars-cov-2 virus from the gi tract
Latest News
2021-09-21 12:47:00 - GlobeNewsWire
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22 Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22
2021-09-15 09:20:00 - PennyStocks
3 Penny Stocks That Top Investors Buying Right Now
Which penny stocks are you watching in September 2021? Here's three for some watchlist inspiration The post 3 Penny Stocks That Top Investors Buying Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-09-14 12:59:13 - Zacks Investment Research
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.
2021-09-14 07:30:00 - GlobeNewsWire
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name. The full text of the letter, which has also been posted to the Company's website, is as follows:
2021-09-13 16:40:06 - Seeking Alpha
AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript
AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript
2021-09-13 09:19:54 - Benzinga
AzurRx BioPharma Announces Reverse Merger With First Wave Bio
AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments. First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).
2021-09-13 06:00:00 - GlobeNewsWire
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI”
2021-09-10 12:45:00 - GlobeNewsWire
AzurRx BioPharma Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021 Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021
2021-09-10 08:30:00 - GlobeNewsWire
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract
2021-09-09 08:30:00 - GlobeNewsWire
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned